Navigation Links
SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
Date:5/3/2010

AMSTERDAM, May 3, 2010 /PRNewswire/ -- SynCo Bio Partners B.V., an award winning GMP biopharmaceutical manufacturer, has expanded its current agreement with OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells. Under the expanded agreement, in addition to antibody OMP-21M18, SynCo will fill batches of OncoMed's investigational products, two additional antibodies in the OncoMed pipeline for use in Phase I and II clinical trials.

Announcing the agreement, Pierre Warffemius, CEO, said, "We are extremely delighted that OncoMed and SynCo's working relationship continues to strengthen and that SynCo has been able to support this leading biopharmaceutical company's clinical development effectively over the last two years. We look forward to a continued mutually beneficial collaboration."

Paul J. Hastings, President and CEO of OncoMed, said, "We are delighted to be working with SynCo on the manufacture of our novel antibodies targeting cancer stem cells. SynCo has been a great partner and has delivered excellent performance on our anti-DLL4 antibody, OMP-21M18, which is currently in Phase I clinical trials. Based on our positive experience working with them to date, we can think of no one more qualified than SynCo to continue providing filling operations."

SynCo will fill the OncoMed antibodies at its Amsterdam-based facility. This facility is able to fill a wide range of biopharmaceuticals into vials, including protein, polysaccharide, and live biotherapeutics using the latest automated filling equipment.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth and recurrence. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed's lead candidate, OMP-21M18 is currently in Phase I clinical trials. In addition to OMP-21M18, OncoMed's pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways. Privately-held, OncoMed's investors include: Nomura Phase4 Ventures, US Venture Partners, Latterell Venture Partners, Morgenthaler Ventures, The Vertical Group, Adams Street Partners, De Novo Ventures, Delphi Ventures, Bay Partners and GlaxoSmithKline. Additional information can be found at the company's website: http://www.oncomed.com.

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience in mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of vaccines, recombinant proteins and live-biotherapeutic products in its state-of-the-art, GMP-licensed facilities since inception in 2000. Focused solely on biopharmaceuticals, SynCo acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo's team is committed to exceeding customer expectations, taking a truly collaborative approach to contract manufacturing. For more information, please visit http://www.syncobiopartners.com


'/>"/>
SOURCE SynCo Bio Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Cellectar Expands Clinical Management Team
5. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. PAREXEL Expands Global Clinical Pharmacology Capabilities
9. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
10. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
11. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... to reach USD 2.06 billion by 2022, according ... Inc. Increasing consumer awareness towards a healthy lifestyle ... next seven years.      (Logo: ... intake coupled with rising health treatment expenditure has ...
(Date:4/26/2016)... April 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... presentation at the Deutsche Bank 41 st Annual Health ... EDT. You are invited to listen to the ... or access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded ... conclusion of the live event and accessible at the links ...
(Date:4/26/2016)... 26, 2016 Research and Markets has ... Risk Analysis of the Biological Medicine Industry in China ... report analyzes the financial assessment and credit risk of ... . The report provides readers with an in-depth understanding ... participants should be aware of. It considers current and ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition Duchenne, a ... and funding for Duchenne research, participated in the April 25 U.S. Food and ... Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in Hyattsville, Maryland ...
(Date:4/29/2016)... ... , ... Pro3rd Grunge is a package of 30 grunge-themed lower thirds created ... characters, and locations without having to set a single keyframe. Choose from a variety ... components. Simply select a preset and drag it into the FCPX timeline. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Orthodontics ... their founders, Dr. Gemmi and Dr. Middleberg, were asked by Invisalign ... nation. During the seminar, titled “Advancing the Biomechanics of Invisalign Clear Aligners,” ...
(Date:4/28/2016)... ... 2016 , ... Sanford Health’s work in cellular therapy and ... and leaders from Sanford Health were selected to participate in the “ Third ... and receive the 2016 Pontifical Key Innovation Award at the Vatican. , The ...
(Date:4/28/2016)... , ... April 28, 2016 , ... Head Over Heels ... 9 Western Championships. The competition will be held at the University of Montana on ... gymnasts west of the Mississippi River. , In order to qualify, Varize needed to ...
Breaking Medicine News(10 mins):